Sanofi (NASDAQ:SNY) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Sanofi (NASDAQ:SNY) issued its earnings results on Thursday. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05, Zacks reports. Sanofi had a net margin of 9.60% and a return on equity of 38.98%. The firm had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter last year, the company posted $0.95 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year.

Sanofi Stock Performance

SNY stock traded down $0.70 during midday trading on Friday, hitting $52.40. 1,994,568 shares of the stock traded hands, compared to its average volume of 2,357,098. The firm has a market cap of $132.72 billion, a P/E ratio of 26.33, a PEG ratio of 1.63 and a beta of 0.59. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The stock’s fifty day simple moving average is $49.21 and its 200-day simple moving average is $48.69. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.72.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Friday. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.